The non-animal alternatives testing market entails of sales of non-animal alternatives testing products and services that do not contain the practice of animals for tests to determine the protection standards for products. The non-animal alternatives testing market includes testing for drugs, cosmetic products using non- animal testing procedures. Organs-on-chip, In-vitro test, In-silico test are some examples of methods and methodologies used as an alternate to animal testing.
According to the report analysis, ‘Non-Animal Alternatives Testing Market Global Report 2020-30’ states that the global non-animal alternatives testing market was worth USD 1.11 billion throughout 2019. It is predicted to augment at a compound annual growth rate (CAGR) of 11.62% and reach USD 1.65 billion by 2023. The corporates in the non-animal testing market are progressively more investing in technologies such as organs on the chip technology as an alternate to animal testing. Organs- on the- chip method encompasses human cells on a chip which mimics the structure and function of human organs and organs system instead of utilizing of animal for the test.
Following the trend, during 2018,
Emulate was financed an amount of USD 36 million from its founder's fund and
ALS Investment Fund, SciFi VC, Glass Wall Syndicate Association to prolonged
its biological capabilities to Liver-Chip, Intestine-Chip, Lung-Chip, and
Brain-Chip, and to its human-relevant replicas of thrombosis and immune system
modulation. Moreover, the ALS Investment Fund, SciFi VC and Glass Wall
Syndicate Association are venture capital and private equity firm that backings
and finances biotech corporates.
In addition, during 2018, Thermo
Fisher Scientific Inc., a USA based life sciences research company, obtained
Advanced Bioprocessing business from Becton, Dickinson and Company for USD 477
million in cash. Through this acquisition Thermo Fisher Scientific Inc. focused
to enlarge its bioproduction portfolio by utilizing the cell-culture media products
of the Becton, Dickinson and Company. The Becton, Dickinson and Company is a
USA reliant medical device company.
However, according to Cruelty Free
International, during 2018, around the UK almost 40 eye irritation tests,
10,275 acute lethal toxicity tests, and 638 pyrogenicity experiments were
accompanied on live rabbits. Cruelty Free International is an U.K based animal
security and advocacy group. The legal requirements in some countries for
necessary animal testing will limit the growth of the market.
Whereas, the assistance from the
government and non-governmental organizations booms the growth of the
non-animal testing market. The government organizations implements laws and
regulations, promotions funds to support the non-animal testing approaches such
as tests on human volunteers, advanced computer-modelling techniques and also
funds studies with the human volunteer. In order to assistance the non-animal
testing, US Environmental Protection Agency (EPA), during 2019, awarded USD
4.25 million to the USA based universities involving Johns Hopkins University,
Vanderbilt University, Oregon State University, and the University of
California to research for substitute tests replacing animals with non-animal
alternatives and to generate the test procedures less hurting to the laboratory
animals. Similar research programs to encourage non-animal testing measures are
also initiated by regions such as Denmark, Brazil, Germany, Switzerland,
Australia, China and Korea. The constant assistance from the government propels
the growth of the non-animal testing market. Therefore, in the near years, it
is predicted that the market of non-animal alternatives testing will increase
around the globe more significantly.
For More Information, Click on the Link Below:-
Global
Non-Animal Alternatives Testing Market
Related Report:-
Animal
Testing And Non-Animal Alternative Testing Global Market Opportunities And
Strategies To 2035
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
No comments:
Post a Comment